Clene (NASDAQ:CLNN) Major Shareholder Sells $444,695.22 in Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 56,577 shares of the business’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $7.86, for a total value of $444,695.22. Following the completion of the sale, the insider owned 594,368 shares of the company’s stock, valued at $4,671,732.48. This trade represents a 8.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Thursday, December 18th, Chidozie Ugwumba sold 5,816 shares of Clene stock. The stock was sold at an average price of $6.33, for a total value of $36,815.28.
• On Wednesday, December 17th, Chidozie Ugwumba sold 2,884 shares of Clene stock. The stock was sold at an average price of $6.61, for a total transaction of $19,063.24.
• On Tuesday, December 16th, Chidozie Ugwumba sold 7,030 shares of Clene stock. The stock was sold at an average price of $6.31, for a total transaction of $44,359.30.
• On Monday, December 15th, Chidozie Ugwumba sold 10,580 shares of Clene stock. The stock was sold at an average price of $6.49, for a total transaction of $68,664.20.
• On Friday, December 12th, Chidozie Ugwumba sold 7,603 shares of Clene stock. The shares were sold at an average price of $6.79, for a total transaction of $51,624.37.
• On Thursday, December 11th, Chidozie Ugwumba sold 10,907 shares of Clene stock. The stock was sold at an average price of $6.81, for a total transaction of $74,276.67.
• On Wednesday, December 10th, Chidozie Ugwumba sold 9,921 shares of Clene stock. The stock was sold at an average price of $6.42, for a total transaction of $63,692.82.
• On Tuesday, December 9th, Chidozie Ugwumba sold 15,031 shares of Clene stock. The shares were sold at an average price of $5.95, for a total value of $89,434.45.
• On Monday, December 8th, Chidozie Ugwumba sold 21,463 shares of Clene stock. The stock was sold at an average price of $5.70, for a total value of $122,339.10.
• On Friday, December 5th, Chidozie Ugwumba sold 37,235 shares of Clene stock. The stock was sold at an average price of $5.94, for a total value of $221,175.90.

Clene Price Performance

NASDAQ:CLNN opened at $6.68 on Friday. The firm has a market capitalization of $69.00 million, a P/E ratio of -1.97 and a beta of 0.79. The business has a 50 day simple moving average of $8.51 and a 200 day simple moving average of $6.23. Clene Inc. has a 12-month low of $2.28 and a 12-month high of $13.50.

Clene (NASDAQ:CLNN) last issued its earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.06 million. Research analysts anticipate that Clene Inc. will post -5.19 EPS for the current fiscal year.

Hedge Funds Weigh In On Clene

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Scoggin Management LP raised its stake in shares of Clene by 75.1% in the 3rd quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock worth $1,506,000 after buying an additional 107,250 shares in the last quarter. Lunt Capital Management Inc. grew its holdings in Clene by 71.2% during the second quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock worth $199,000 after acquiring an additional 21,217 shares during the period. Jane Street Group LLC bought a new stake in Clene in the second quarter worth about $47,000. Finally, Jones Financial Companies Lllp acquired a new stake in Clene in the 3rd quarter valued at about $29,000. 23.28% of the stock is owned by institutional investors.

Clene News Roundup

Here are the key news stories impacting Clene this week:

• Positive Sentiment: Sell‑side support remains — several research firms (Benchmark, UBS, D. Boral Capital) continue to carry Buy ratings and elevated targets, which can limit downside and support rebounds. MarketBeat CLNN
• Neutral Sentiment: Institutional activity mixed — some hedge funds increased or initiated positions (e.g., Scoggin Management added shares), meaning a portion of supply is being absorbed by institutions rather than retail. MarketBeat Holdings
• Negative Sentiment: Material insider selling by a major shareholder — Ugwumba disclosed many transactions from Dec. 3–17 totaling roughly ~258k shares sold across multiple days (including a 72,748 share sale on Dec. 4 that was reported as a 12.24% position reduction). Heavy, concentrated selling from a >10% holder puts clear downward pressure and likely explains the intraday weakness. InsiderTrades Article
• Negative Sentiment: Weak recent operating results — the company missed Q3 revenue and EPS expectations (reported -$0.85 vs. consensus -$0.60; revenue essentially immaterial), keeping the story speculative and increasing sensitivity to insider flows. SEC Filing

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. D. Boral Capital restated a “buy” rating and issued a $23.00 price target on shares of Clene in a research note on Wednesday, December 10th. UBS Group restated a “buy” rating on shares of Clene in a research report on Wednesday, December 3rd. Benchmark reaffirmed a “buy” rating on shares of Clene in a research note on Thursday, December 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Clene in a research note on Tuesday, October 14th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Clene has an average rating of “Moderate Buy” and a consensus target price of $32.60.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).